QRxPharma scores Canadian licensing deal for MoxDuo
10 October, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has secured a potentially lucrative licensing deal covering the Canadian market for its pain relief drug, MoxDuo IR, which is currently awaiting marketing approval in Canada and the US.
AusBiotech welcomes McKeon Review focus on translation
09 October, 2012 by AusBiotechThe McKean Review has reported recently, providing a consultation paper for comment until the end of October.
Vaxxas partners with Merck on Nanopatch needle-free vaccine patch
09 October, 2012 by Dylan Bushell-EmblingStart-up Vaxxas has picked up its first major pre-licensing and evaluation deal for Nanopatch, the needle-free vaccine technology developed at the AIBN, collaborating with Merck.
AtCor wins $3.2m SphygmoCor deal
08 October, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has won a $3.2 million contract to supply its SphygmoCor specialist blood pressure monitoring systems for multiple clinical trial sites.
Bluechiip cashes in on R&D Tax Incentive
04 October, 2012 by Dylan Bushell-EmblingBluechiip (ASX:BCT) has become the latest life science company to take advantage of the government's R&D Tax Incentive.
Sirtex sales continue to grow
04 October, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has reported another strong quarter for its SIR-Spheres targeted radioactive liver cancer treatments, reporting year-on-year sales growth of 37% for Q1.
AusBiotech submits to Productivity Commission on compulsory licensing
04 October, 2012 by AusBiotechAusBiotech has provided a submission in response to the Productivity Commission’s discussion paper on its review into compulsory licensing in the patents system.
Sunshine Heart to start C-Pulse Heart Assist trial in US
03 October, 2012 by Dylan Bushell-EmblingUS Food and Drug Administration (FDA) conditional approval for an investigational device exemption (IDE) for Sunshine Heart’s (ASX:SHC) flagship C-Pulse Heart Assist System paves the way for the company to conduct a key clinical trial of the system to support its FDA application.
BioDiem launches $2.5m rights issue
02 October, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has commenced an up to $2.5m rights issue to raise funds for its various vaccine and infectious disease development programs.
Vale Nancy Millis AC, Australia’s “first lady” of biotechnology
02 October, 2012 by Tim DeanThe Australian life sciences community is mourning the loss of Emeritus Professor Nancy Millis AC, who passed away this weekend at the age of 90.
AusBiotech & Beacon to partner on key investment events
02 October, 2012 by AusBiotechAusBiotech and Beacon Events, organiser of the largest resource sector investor event in the Asia Pacific Region – Mines and Money – have announced a partnership to deliver biotechnology investor meetings in Hong Kong and Sydney until 2015.
Avita gets more US army funds for ReCell trial
28 September, 2012 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has secured additional funding from the US Department of Defense to support the FDA trial for its ReCell Spray-On-Skin in burn injuries.
NZP to produce drug for NIH trial
28 September, 2012 by Dylan Bushell-EmblingNew Zealand Pharmaceuticals (NZP) has announced it will be involved in a phase I trial treating rare genetic disease Hereditary Inclusion Body Myopathy (HIBM) launched by the US National Institutes of Health (NIH).
Kinomics research centre to develop next generation drugs
28 September, 2012 by Tim DeanA new dual-site research centre focusing on kinomics is now open for business, focusing on developing new drugs to battle cancer and other diseases.
CSL near diabetes breakthrough
27 September, 2012 by Dylan Bushell-EmblingA drug candidate developed by CSL (ASX:CSL) which blocks the protein VEGF-B prevented the development or progression of type-2 diabetes in three separate animal trials.
